Alterations in the promoter region of the FATP5 gene are associated with increased FATP5 expression, which exacerbates steatosis in the liver of MASLD patients (Auinger et al., 2010). The gene discussed is SLC27A5; the disease is metabolic dysfunction-associated steatotic liver disease.